Your browser doesn't support javascript.
loading
Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study.
Schrijver, Lieske H; Olsson, Håkan; Phillips, Kelly-Anne; Terry, Mary Beth; Goldgar, David E; Kast, Karin; Engel, Christoph; Mooij, Thea M; Adlard, Julian; Barrowdale, Daniel; Davidson, Rosemarie; Eeles, Ros; Ellis, Steve; Evans, D Gareth; Frost, Debra; Izatt, Louise; Porteous, Mary E; Side, Lucy E; Walker, Lisa; Berthet, Pascaline; Bonadona, Valérie; Leroux, Dominique; Mouret-Fourme, Emmanuelle; Venat-Bouvet, Laurence; Buys, Saundra S; Southey, Melissa C; John, Esther M; Chung, Wendy K; Daly, Mary B; Bane, Anita; van Asperen, Christi J; Gómez Garcia, Encarna B; Mourits, Marian J E; van Os, Theo A M; Roos-Blom, Marie-José; Friedlander, Michael L; McLachlan, Sue-Anne; Singer, Christian F; Tan, Yen Y; Foretova, Lenka; Navratilova, Marie; Gerdes, Anne-Marie; Caldes, Trinidad; Simard, Jacques; Olah, Edith; Jakubowska, Anna; Arver, Brita; Osorio, Ana; Noguès, Catherine; Andrieu, Nadine.
Affiliation
  • Schrijver LH; Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Olsson H; Department of Oncology, Lund University Hospital.
  • Phillips KA; Lund University, Lund, Sweden; Sir Peter MacCallum Department of Oncology.
  • Terry MB; Division of Cancer Medicine.
  • Goldgar DE; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
  • Kast K; Department of Epidemiology.
  • Engel C; Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT.
  • Mooij TM; Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
  • Adlard J; Oncology and Pathology, Department of Clinical Sciences Lund.
  • Barrowdale D; Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Germany.
  • Davidson R; Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Eeles R; Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK.
  • Ellis S; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, UK.
  • Evans DG; Department of Clinical Genetics, South Glasgow University Hospitals, Glasgow, UK.
  • Frost D; Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.
  • Izatt L; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, UK.
  • Porteous ME; Genomic Medicine, Manchester Academic Health Sciences Centre, Institute of Human Development, Manchester University, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • Side LE; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge, UK.
  • Walker L; Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
  • Berthet P; South East of Scotland Regional Genetics Service, Western General Hospital, Edinburgh, UK.
  • Bonadona V; North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Trust, London, UK.
  • Leroux D; Oxford Regional Genetics Service, Churchill Hospital, Oxford, UK.
  • Mouret-Fourme E; Centre François Baclesse, Caen, France.
  • Venat-Bouvet L; Université Claude Bernard Lyon 1, Villeurbanne, France.
  • Buys SS; CHU de Grenoble, Hôpital Couple-Enfant, Département de Génétique, Grenoble, France.
  • Southey MC; Service de Génétique Oncologique, Hôpital René Huguenin/Institut Curie, Saint-Cloud, France.
  • John EM; Hôpital Universitaire Dupuytren, Service d'Oncologie Médicale, Limoges, France.
  • Chung WK; Department of Medicine, Huntsman Cancer Institute, Salt Lake City, UT.
  • Daly MB; Genetic Epidemiology Laboratory, Department of Pathology.
  • Bane A; Precision Medicine, School of Clinical Science at Monash Health, Monash University, Victoria, Australia.
  • van Asperen CJ; Department of Epidemiology, Cancer Prevention Institute of California, Fremont, CA.
  • Gómez Garcia EB; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.
  • Mourits MJE; Department of Pediatrics and Medicine, Columbia University, New York, NY.
  • van Os TAM; Division of Population Science, Fox Chase Cancer Center, Philadelphia, PA.
  • Roos-Blom MJ; Department of Pathology and Molecular Medicine, Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, Ontario, Canada.
  • Friedlander ML; Department of Oncology-Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • McLachlan SA; Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.
  • Singer CF; Department of Clinical Genetics and GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Tan YY; Department of Gynaecologic Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Foretova L; Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands.
  • Navratilova M; Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Gerdes AM; Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.
  • Caldes T; Department of Medical Oncology, Prince of Wales Hospital, Randwick, Australia.
  • Simard J; Department of Medicine, St. Vincent's Hospital, University of Melbourne, Parkville, Victoria, Australia.
  • Olah E; Division of Cancer Medicine.
  • Jakubowska A; Department of Medical Oncology, St Vincent's Hospital, Fitzroy, Australia.
  • Arver B; Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Osorio A; Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Noguès C; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic, Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology.
  • Andrieu N; Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic, Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology.
JNCI Cancer Spectr ; 2(2): pky023, 2018 Apr.
Article in En | MEDLINE | ID: mdl-31360853
ABSTRACT

BACKGROUND:

For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use and breast cancer (BC) risk is still unclear.

METHODS:

Breast camcer risk associations were estimated from OCP data on 6030 BRCA1 and 3809 BRCA2 mutation carriers using age-dependent Cox regression, stratified by study and birth cohort. Prospective, left-truncated retrospective and full-cohort retrospective analyses were performed.

RESULTS:

For BRCA1 mutation carriers, OCP use was not associated with BC risk in prospective analyses (hazard ratio [HR] = 1.08, 95% confidence interval [CI] = 0.75 to 1.56), but in the left-truncated and full-cohort retrospective analyses, risks were increased by 26% (95% CI = 6% to 51%) and 39% (95% CI = 23% to 58%), respectively. For BRCA2 mutation carriers, OCP use was associated with BC risk in prospective analyses (HR = 1.75, 95% CI = 1.03 to 2.97), but retrospective analyses were inconsistent (left-truncated HR = 1.06, 95% CI = 0.85 to 1.33; full cohort HR = 1.52, 95% CI = 1.28 to 1.81). There was evidence of increasing risk with duration of use, especially before the first full-term pregnancy (BRCA1 both retrospective analyses, P < .001 and P = .001, respectively; BRCA2 full retrospective analysis, P = .002).

CONCLUSIONS:

Prospective analyses did not show that past use of OCP is associated with an increased BC risk for BRCA1 mutation carriers in young middle-aged women (40-50 years). For BRCA2 mutation carriers, a causal association is also not likely at those ages. Findings between retrospective and prospective analyses were inconsistent and could be due to survival bias or a true association for younger women who were underrepresented in the prospective cohort. Given the uncertain safety of long-term OCP use for BRCA1/2 mutation carriers, indications other than contraception should be avoided and nonhormonal contraceptive methods should be discussed.
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Language: En Journal: JNCI Cancer Spectr Year: 2018 Document type: Article Affiliation country: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Language: En Journal: JNCI Cancer Spectr Year: 2018 Document type: Article Affiliation country: Netherlands